OncoCyte Corp (OCX) Stock Rating Upgraded by Zacks Investment Research
OncoCyte Corp (NYSEMKT:OCX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Separately, Chardan Capital initiated coverage on OncoCyte Corp in a research report on Thursday, February 23rd. They issued a “buy” rating and a $6.50 price target for the company. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $6.81.
Shares of OncoCyte Corp (NYSEMKT:OCX) opened at 5.80 on Friday. OncoCyte Corp has a 12-month low of $3.10 and a 12-month high of $7.95. The stock’s 50 day moving average price is $5.41 and its 200-day moving average price is $5.39. The firm’s market cap is $170.29 million.
OncoCyte Corp (NYSEMKT:OCX) last issued its earnings results on Monday, February 27th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, analysts predict that OncoCyte Corp will post ($0.49) earnings per share for the current fiscal year.
Your IP Address:
About OncoCyte Corp
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.